Titanium (Ti) is broadly used for clinical purposes in various medical fields related to bone repair because of its favorable mechanical properties and its ability to osseointegrate in host bone tissue. Nowadays, Ti surfaces can be functionalized in order to provide potentially beneficial additional properties. In this review, we summarize different surface modifications of Ti implants, focusing on biological relevance and the biological issues targeted by each specific approach. We first define the historical relevance of Ti as an implantable material, the osseointegration process, and the main complications related to it before describing the biological rationale which motivates Ti surface modification in implantable devices. Then, we explore a variety of physical and chemical modifications feasible on Ti surfaces. Thereafter, we focus on inorganic and organic coatings being developed for implantable Ti devices that are currently under investigation. Finally, we summarize the surface-modification approaches clinically available or undergoing clinical trials.

Osteosarcoma (OS) is the most common type of primary solid tumor that develops in bone. Although standard chemotherapy has significantly improved long-term survival over the past few decades, the outcome for those patients with metastatic or recurrent OS remains dismally poor and, therefore, novel agents and treatment regimens are urgently required. A hypothesis to explain the resistance of OS to chemotherapy is the existence of drug resistant CSCs with progenitor properties that are responsible of tumor relapses and metastasis. These subpopulations of CSCs commonly emerge during tumor evolution from the cell-of-origin, which are the normal cells that acquire the first cancer-promoting mutations to initiate tumor formation. In OS, several cell types along the osteogenic lineage have been proposed as cell-of-origin. Both the cell-of-origin and their derived CSC subpopulations are highly influenced by environmental and epigenetic factors and, therefore, targeting the OS-CSC environment and niche is the rationale for many recently postulated therapies. Likewise, some strategies for targeting CSC-associated signaling pathways have already been tested in both preclinical and clinical settings. This review recapitulates current OS cell-of-origin models, the properties of the OS-CSC and its niche, and potential new therapies able to target OS-CSCs.

No abstract

We report the preparation of microporous functional polymer surfaces that have been proven to be selective surfaces toward eukaryotic cells while maintaining antifouling properties against bacteria. The fabrication of functional porous films has been carried out by the breath figures approach that allowed us to create porous interfaces with either poly(ethylene glycol) methyl ether methacrylate (PEGMA) or 2,3,4,5,6-pentafluorostyrene (5FS). For this purpose, blends of block copolymers in a polystyrene homopolymer matrix have been employed. In contrast to the case of single functional polymer, using blends enables us to vary the chemical distribution of the functional groups inside and outside the formed pores. In particular, fluorinated groups were positioned at the edges while the hydrophilic PEGMA groups were selectively located inside the pores, as demonstrated by TOF-SIMS. More interestingly, studies of cell adhesion, growth, and proliferation on these surfaces confirmed that PEGMA functionalized interfaces are excellent candidates to selectively allow cell growth and proliferation while maintaining antifouling properties.

Introducing new hydrogels for the support of confluent cell growth and from which cell sheets can be easily detached or transplanted.

No abstract

No abstract

No abstract